HUGO-GT™: Advanced Humanized Mouse Models for Gene Therapy Research
Have you ever felt the profound disconnect between a promising gene therapy in the lab and its potential in the clinic? You’ve identified the target, designed the therapeutic, and are ready to test it. Yet, the very models meant to predict human outcomes become the first and most significant hurdle. You're forced to rely on models with randomly inserted human cDNA, leading to unpredictable expression levels and off-target effects. Or perhaps you're using a conventional knockout model that doesn't fully capture the nuances of a human genetic disease.
This is the silent frustration in countless gene therapy labs. It’s the costly delay of troubleshooting models that don't truly mimic human physiology. It’s the uncertainty that gnaws at you as you prepare for preclinical trials, wondering if your data, built on a flawed foundation, will hold up. The professional cost is measured in stalled projects and retracted papers; the emotional cost is the delayed hope for patients waiting for a breakthrough. What if you could bridge this translational gap? What if your in vivo model wasn't a compromise, but a precise reflection of the human condition you aim to cure?
Overcoming Translational Hurdles in Gene Therapy with Precise In Vivo Models
Imagine a research reality where your animal model is no longer the weakest link, but your most powerful asset. Picture heading into your next experiment with complete confidence, knowing the human gene you're targeting is expressed in the right place, at the right time, and under the control of its natural biological machinery. Envision skipping the months, or even years, of model validation uncertainties and moving directly to efficacy testing with a model engineered for clinical relevance.
This isn't an incremental improvement; it's a fundamental shift in how gene therapy research is conducted. It's a world where your in vivo data translates seamlessly to clinical applications because your model was built from the ground up to mirror human biology. In this reality, you can accelerate your pipeline, publish with greater impact, and move your therapeutic candidates toward IND-enabling studies with a degree of certainty that was previously unattainable. This is the future of gene therapy research—a future where your focus returns to curing disease, not questioning your tools.
HUGO-GT™: Full-Length Human Gene Integration with Natural Regulation
This vision of accelerated, reliable research is now possible. Cyagen’s HUGO-GT™ (Humanized Genomic Ortholog for Gene Therapy) platform was developed specifically to overcome the limitations of traditional models, providing you with a clear and direct path to clinically relevant data. By leveraging advanced TurboKnockout-Pro based homologous recombination, we empower your research with a new class of humanized models.
You can achieve faithful, tissue-specific gene expression because our HUGO-GT™ technology replaces the entire coding sequence (CDS) and introns of a mouse gene with its full-length human counterpart. Unlike simple cDNA insertions, this preserves the native mouse promoter and critical regulatory elements, ensuring that the human gene is expressed under authentic physiological control.
You can accurately model complex genetic diseases and test human-specific therapies because HUGO-GT™ accommodates extremely large gene insertions—over 200kb. This allows for the complete humanization of even the largest and most complex genes, including all their splice variants, providing a far superior platform for studying diseases like Retinitis Pigmentosa or Stargardt disease.
You can trust your model’s biological function because every HUGO-GT™ model undergoes rigorous validation. We confirm everything from mRNA and protein expression to the preservation of tissue architecture and physiological function, giving you a fully characterized model ready for experimentation.
You can accelerate your research timeline significantly because our streamlined, high-efficiency process delivers these sophisticated models with industry-leading turnaround times. Stop waiting on complex breeding schemes and start getting answers.
What HUGO-GT™ Delivers:
- Complete Human Gene Integration: Insertion of the full-length human gene-coding sequence and introns.
- Preserved Natural Regulation: Retention of endogenous mouse promoters and enhancers for physiological expression.
- Unmatched Capacity: Ability to insert large fragments (>200kb), essential for complex genes.
- Comprehensive Validation: Rigorous confirmation through qPCR, Western Blot, IHC, and functional assays (e.g., Electroretinography - ERG).
- Speed and Efficiency: A proven platform that gets validated models into your hands faster.
Validated Solutions for Complex Diseases: RHO and ABCA4 Model Case Studies
For over 19 years, Cyagen has partnered with thousands of researchers and institutions around the globe, not as a vendor, but as a dedicated collaborator in solving complex biological questions. We understand the pressures of academic and biopharma R&D, and we built the HUGO-GT™ platform in response to the challenges we saw our partners facing in the gene therapy space. Our experience is not just in building models, but in understanding the scientific outcomes they are meant to drive.
This collaborative approach is proven in the success of the models we have delivered. Researchers working on ocular diseases, for example, have used HUGO-GT™ to overcome significant hurdles:
- The Rhodopsin (RHO) Model: For studies in Retinitis Pigmentosa, we developed a humanized RHO mouse where the mouse Rho gene is replaced by the human RHO gene. The protein encoded by the human gene is normally expressed in the mouse. Rigorous validation confirmed that the mice retained normal retinal function, as measured by ERG. This provided a validated, stable platform for testing novel AAV-based therapies.
- The ABCA4 Model: Stargardt disease research has been hampered by the enormous size of the ABCA4 gene. Using HUGO-GT™, we successfully integrated the full-length human ABCA4 coding sequence. Our data confirmed faithful mRNA and protein expression, creating a groundbreaking model for testing therapies targeting this challenging gene.
These are not just models; they are solutions born from a deep understanding of the scientific journey. They represent what is possible when cutting-edge technology is guided by the needs of the researcher—the hero of the story.
Accelerate Your IND-Enabling Studies with Expert Gene Targeting Consultation
The path from a complex biological question to a life-changing therapy is challenging. The tools you use along the way should not add to that burden. HUGO-GT™ was designed to remove obstacles, instill confidence, and accelerate your progress toward the clinic.
Empower your research with a model that is as sophisticated as your science.
Explore our growing repository of validated, ready-to-use HUGO-GT™ models.
Or, if your research demands a novel approach:
Talk to a gene targeting strategist today for a free consultation and model design plan. Let's build your next breakthrough together.
